Being the basis of Her-2 positive breast cancer treatment, trastuzumab was a humanized monoclonal antibody targeting at extracellular domain of Her-2, and previous studies demonstrated blocking Her-2 mediated signaling pathway was the main mechanism of its efficacy. Here, ERBB2 is linked to breast cancer.